Review Article|Articles in Press

Insulin Therapy in Small Animals, Part 3: Dogs

Published:March 09, 2023DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Veterinary Clinics: Small Animal Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. McAllister M. Feline and canine diabetes prevalence in the USA. Banfield State of Pet Helath, 2020, Available at:, Accessed June 3, 2022.

        • Shields E.J.
        • et al.
        Extreme Beta-Cell Deficiency in Pancreata of Dogs with Canine Diabetes.
        PLoS One. 2015; 10: e0129809
        • Gilor C.
        • Pires J.
        • Greathouse R.
        • et al.
        Loss of sympathetic innervation to islets of Langerhans in canine diabetes and pancreatitis is not associated with insulitis.
        Sci Rep. 2020; 10
        • Gilor C.
        • Graves T.K.
        Synthetic Insulin Analogs and Their Use in Dogs and Cats.
        Vet Clin North Am Small Anim Pract. 2010; 40
        • Clark M.
        • Thomaseth K.
        • Heit M.
        • et al.
        Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs.
        J Vet Pharmacol Ther. 2012; 35: 342-350
        • Graham P.A.
        • Nash A.S.
        • McKellar Q.A.
        Pharmacokinetics of a porcine insulin zinc suspension in diabetic dogs.
        J Small Anim Pract. 1997; 38: 434-438
        • Fleeman L.M.
        • Rand J.S.
        • Morton J.M.
        Pharmacokinetics and pharmacodynamics of porcine insulin zinc suspension in eight diabetic dogs.
        Vet Rec. 2009; 164: 232-237
        • Owens D.R.
        • Bolli G.B.
        Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
        Diabetes Technol Ther. 2008; 10: 333-349
        • Havelund S.
        • Plum A.
        • Ribel U.
        • et al.
        The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.
        Pharm Res (N Y). 2004; 21: 1498-1504
        • Heise T.
        • Nosek L.
        • Rønn B.B.
        • et al.
        Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
        Diabetes. 2004; 53: 1614-1620
        • Miller M.
        • Pires J.
        • Crakes K.
        • et al.
        Day-to-Day Variability of Porcine Lente, Insulin Glargine 300 U/mL and Insulin Degludec in Diabetic Dogs.
        J Vet Intern Med. 2021; 35: 2131-2139
        • De Marco V.
        • T G.
        • Chen G.
        Day-to-day variability of serial blood glucose curves in diabetic dogs treated with twice daily NPH or insulin detemir.
        J Vet Intern Med. 2015; 29: 1173
        • Fleeman L.M.
        • Rand J.S.
        Evaluation of day-to-day variability of serial blood glucose concentration curves in diabetic dogs.
        J Am Vet Med Assoc. 2003; 222: 317-321
        • Ward C.R.
        • Christiansen K.
        • Li J.
        • et al.
        Field efficacy and safety of protamine zinc recombinant human insulin in 276 dogs with diabetes mellitus.
        Domest Anim Endocrinol. 2020; 75: 106575
        • Maggiore A. Della
        • Nelson R.W.
        • Dennis J.
        • et al.
        Efficacy of protamine zinc recombinant human insulin for controlling hyperglycemia in dogs with diabetes mellitus.
        J Vet Intern Med. 2012; 26: 109-115
        • Gilor C.
        • Fracassi F.
        • Berg A.
        • et al.
        Once-daily insulin glargine 300 U/ml for the treatment of canine diabetes mellitus [Abstract].
        J Vet Intern Med. 2022; 36: 2277
        • Oda H.
        • Mori A.
        • Ishii S.
        • et al.
        Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs.
        J Vet Med Sci. 2018; 80: 1720-1723
        • Palm C.A.
        • Boston R.C.
        • Refsal K.R.
        • et al.
        An investigation of the action of Neutral Protamine Hagedorn human analogue insulin in dogs with naturally occurring diabetes mellitus.
        J Vet Intern Med. 2009; 23: 50-55
        • Monroe W.E.
        • Laxton D.
        • Fallin E.A.
        • et al.
        Efficacy and safety of a purified porcine insulin zinc suspension for managing diabetes mellitus in dogs.
        J Vet Intern Med. 2005; 19: 675-682
        • Mori A.
        • Sako T.
        • Lee P.
        • et al.
        Comparison of time-action profiles of insulin glargine and NPH insulin in normal and diabetic dogs.
        Vet Res Commun. 2008; 32: 563-573
        • Sako T.
        • Mori A.
        • Lee P.
        • et al.
        Time-action profiles of insulin detemir in normal and diabetic dogs.
        Res Vet Sci. 2011; 90: 396-403
        • Fracassi F.
        • Corradini S.
        • Hafner M.
        • et al.
        Detemir insulin for the treatment of diabetes mellitus in dogs.
        J Am Vet Med Assoc. 2015; 247: 73-78
        • Fink H.
        • Herbert C.
        • Gilor C.
        Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.
        Domest Anim Endocrinol. 2018, 17-30; 64